Nucleic acid therapeutics have emerged as new class of potential drugs for targeting and treatment of various diseases. In recent years, there has been a considerable interest in finding appropriate technologies to formulate nucleic acids into appropriate and bioavailable dosage forms, especially the mRNA. As a result of the introduction of life saving COVID-19 vaccines, and the launch of small interfering RNA (siRNA) as polyneuropathy drug by Alnylam, the industry is renewing interests in the next generation of lipid nanoparticle technology for delivery of mRNA therapeutics for cancers, anti-inflammatory, and rare diseases, among others. Learn more about Nucleic acid therapeutics in this article from Ascendia® Pharmaceuticals, Inc.